samedan logo
 
 
 
spacer
home > ebr > spring 2019 > opportunities and challenges in cancer innovations
PUBLICATIONS
European Biopharmaceutical Review

Opportunities and Challenges in Cancer Innovations

Progress is being made in the long-standing battle to effectively treat and control cancer. The National Cancer Institute projects that nearly five million more US citizens are expected to survive cancer in 2026 than in 2016 (1). Therapeutic tools like nextgeneration sequencing and advances in immunotherapy are just two ways that fundamental scientific breakthroughs and innovative thinking are moving the potential for cancer treatment forward.

One of the most revolutionary breakthroughs in this new era is cell and gene therapy. At its most basic definition, gene therapy (also called human gene transfer) is the therapeutic delivery of nucleic acid into a patient’s cells as a drug to treat disease. According to The Journal of Gene Medicine, somewhere around 2,600 gene therapy clinical trials have been undertaken in 38 countries around the world as of November 2017 (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Ger Brophy is Executive Vice President of Biopharma Production at Avantor. In his current role, he is responsible for developing and implementing the company’s biopharma production and supporting the current and future needs of customers. Prior to joining Avantor, Ger held a variety of R&D, strategy, advanced systems, and business development positions in the healthcare space with GE Healthcare Life Sciences, GE Healthcare Medical Diagnostics, and Amersham for nearly 30 years. He earned a BSc in biotechnology as well as a PhD in molecular biology from Dublin City University, Ireland.
spacer
Dr Ger Brophy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AirBridgeCargo Airlines completes a series of charter flights with packaging machines for COVID-19 associated items

AirBridgeCargo Airlines, part of Volga-Dnepr Group and one of the leaders in air transportations for the healthcare sector, has accomplished five Boeing 747F charter flights with packaging machines for COVID-19 associated materials from Frankfurt (Germany) to Atlanta (USA).
More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement